| HUMAN-TRIAL | evidence | Semaglutide Treatment in Type 1 Diabetes | Semaglutide | human-rct · n = 122 | — |
| HUMAN-TRIAL | evidence | Research Study to Investigate How Well Semaglutide Works Compared to Liraglutide in People Living With Overweight or Obesity | Semaglutide | Weight & fat loss · human-rct · n = 338 | — |
| HUMAN-TRIAL | evidence | Influence of Semaglutide on Pharmacokinetics and Pharmacodynamics of Warfarin and Pharmacokinetics of Metformin in Healthy Subjects | Semaglutide | Glycemic control · n = 24 | — |
| HUMAN-TRIAL | evidence | A Research Study of NNC0165-1562 and Semaglutide in People Who Are Overweight or Obese | Semaglutide | Weight & fat loss · human-rct · n = 37 | — |
| HUMAN-TRIAL | evidence | Epicardial Cardiac Fat-CT (EPIC-CT) | Rybelsus | human-rct · n = 136 | — |
| HUMAN-TRIAL | evidence | Research Study Comparing Different Tablets With the Study Medicine Semaglutide in Healthy Men | Semaglutide | Glycemic control · human-rct · n = 105 | — |
| HUMAN-TRIAL | evidence | Comparison of Body Weight Change Through Different Smeglutide Administration Methods | Semaglutide | human-rct · n = 80 | — |
| HUMAN-TRIAL | evidence | Treatment of GLP-1 for Diabetic Bariatric Patients | Semaglutide | Glycemic control · human-rct · n = 3 | — |
| HUMAN-TRIAL | evidence | Comparison of the Efficacy and Safety of SGLT2i and GLP-1 Receptor Agonists in Obese Patients With Kidney Disease | Semaglutide | Weight & fat loss · human-rct · n = 48 | — |
| HUMAN-TRIAL | evidence | Comparative Effectiveness of Tirzepatide and Semaglutide in Individuals at Cardiovascular Risk | Semaglutide | human-observational · n = 887132 | — |
| HUMAN-TRIAL | evidence | A Study Comparing the Injection Site Pain Experience After the Injection of 2 Different Solutions of Semaglutide With 2 Different Injection Pens, a Compound for the Treatment of Type 2 Diabetes and Obesity | Semaglutide | human-rct · n = 103 | — |
| HUMAN-TRIAL | evidence | Novel Therapeutics and Endothelial Dysfunction in T1DM Patients | Ozempic | Glycemic control · human-rct · n = 90 | — |
| HUMAN-TRIAL | evidence | Proof-of-Concept Study Evaluating Total Body Weight, Physical Function & Safety of Enobosarm in Patients Treated With GLP-1 Receptor Agonist, for Weight Loss | Wegovy | Weight & fat loss · human-rct · n = 200 | — |
| HUMAN-TRIAL | evidence | Trial to Evaluate Cardiovascular and Other Long-term Outcomes With Semaglutide in Subjects With Type 2 Diabetes | Semaglutide | Glycemic control · human-rct · n = 3297 | — |
| HUMAN-TRIAL | evidence | Investigating How CagriSema, Semaglutide and Cagrilintide Regulate Insulin Effects in the Body of People With Type 2 Diabetes | Semaglutide | Glycemic control · human-rct · n = 158 | — |
| HUMAN-TRIAL | evidence | Oral Semaglutide in Patients With Alzheimer's Disease | Rybelsus | Cognition & memory · human-rct · n = 60 | — |
| HUMAN-TRIAL | evidence | Comparison of Injection Site Pain Experience for Semaglutide and Dulaglutide sc | Semaglutide | Weight & fat loss · human-rct · n = 104 | — |
| HUMAN-TRIAL | evidence | A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in The Netherlands, as Part of Local Clinical Practice (SURE NETHERLANDS) | Semaglutide | Glycemic control · human-observational · n = 218 | — |
| HUMAN-TRIAL | evidence | A Randomised Controlled Clinical Trial in Type 2 Diabetes Comparing Semaglutide to Placebo and Liraglutide | NN9535 | Glycemic control · human-rct · n = 415 | — |
| HUMAN-TRIAL | evidence | A Research Study to Look Into the Long-term Effect on Weight Loss of CagriSema in People With Obesity | Semaglutide | Weight & fat loss · human-rct · n = 400 | — |
| HUMAN-TRIAL | evidence | Effect of Semaglutide on Healing of Foot Ulcers in Type 2 Diabetes Patients | Ozempic | Glycemic control · human-rct · n = 52 | — |
| HUMAN-TRIAL | evidence | Oral vs. Subcutaneous Semaglutide in Type 2 Diabetes Mellitus | Semaglutide | Glycemic control · human-observational · n = 212 | — |
| HUMAN-TRIAL | evidence | A Randomised, Single Centre, Double-blind, Two-period, Cross-over Trial in Healthy Subjects Investigating the Bioequivalence Between Subcutaneous Injections of Semaglutide Produced by Two Manufacturing Processes | Semaglutide | Glycemic control · human-rct · n = 28 | — |
| HUMAN-TRIAL | evidence | A Research Study of How the Medicine NNC0480-0389 Taken With Semaglutide Works in the Body of Healthy Japanese Men | Semaglutide | Glycemic control · human-rct · n = 24 | — |
| HUMAN-TRIAL | evidence | The Effect of Oral Semaglutide on Bone Turnover in Patients With T2D: a Randomized Placebo-controlled Clinical Trial | Rybelsus | Glycemic control · human-rct · n = 64 | — |
| HUMAN-TRIAL | evidence | A Proof-of-Concept Study to Evaluate Topical-Lingual Semaglutide in Adults With Obesity | Wegovy | Weight & fat loss · human-rct · n = 40 | — |
| HUMAN-TRIAL | evidence | Research Study to Investigate How Well Semaglutide Tablets Taken Once Daily Work in East Asian People Who Are Overweight or Living With Obesity | Semaglutide | Weight & fat loss · human-rct · n = 201 | — |
| HUMAN-TRIAL | evidence | A Trial Investigating the Influence of Oral Semaglutide on Pharmacokinetics of Ethinylestradiol and Levonorgestrel in an Oral Contraceptive Combination Drug in Healthy Postmenopausal Females | Semaglutide | Glycemic control · n = 25 | — |
| HUMAN-TRIAL | evidence | Research Study Comparing a New Medicine Semaglutide to Liraglutide in People With Type 2 Diabetes | Semaglutide | Glycemic control · human-rct · n = 577 | — |
| HUMAN-TRIAL | evidence | MIST (Metabolic Intervention With Semaglutide and THR-β Therapy) Trial | Semaglutide | Weight & fat loss · human-rct · n = 151 | — |
| HUMAN-TRIAL | evidence | Injectable Semaglutide vs Dulaglutide in Individuals at Cardiovascular Risk | Semaglutide | Weight & fat loss · human-observational · n = 120000 | — |
| HUMAN-TRIAL | evidence | A Study in North Macedonia Investigating Retrospective Data of Glucagon-like Peptide-1 (GLP-1) Participants With Type 2 Diabetes (T2D) in Real World Environment (RWE) Setting (MIRAGE) | Semaglutide | Glycemic control · human-observational · n = 314 | — |
| HUMAN-TRIAL | evidence | A Research Study to See How Well CagriSema Helps People With Excess Body Weight Lose Weight | Semaglutide | Weight & fat loss · human-rct · n = 3400 | — |
| HUMAN-TRIAL | evidence | A Study of Efinopegdutide (MK-6024) in Participants With Nonalcoholic Fatty Liver Disease (NAFLD) (MK-6024-001) | Ozempic | Liver health · human-rct · n = 145 | — |
| HUMAN-TRIAL | evidence | SHIELD-T1D: Shingrix and GLP-1 Agonist for Beta-Cell Preservation in Recent-Onset Type 1 Diabetes. | Ozempic | Glycemic control · human-rct · n = 240 | — |
| HUMAN-TRIAL | evidence | Semaglutide's Efficacy in Achieving Weight Loss for Those With HIV | Ozempic | Weight & fat loss · human-rct · n = 80 | — |
| HUMAN-TRIAL | evidence | A Research Study Looking at New Protein-based Tablets in Healthy Men - Oral Formulation IV | Semaglutide | Glycemic control · human-rct · n = 90 | — |
| HUMAN-TRIAL | evidence | A Biomarker-targeted Clinical Trial to Optimize Treatment for Patients With Chronic Kidney Disease | Semaglutide | Kidney function · human-rct · n = 125 | — |
| HUMAN-TRIAL | evidence | Type 1 Diabetes Impacts of Semaglutide on Cardiovascular Outcomes | Ozempic | Glycemic control · human-rct · n = 60 | — |
| HUMAN-TRIAL | evidence | Semaglutide for Treatment of People With Methamphetamine Use Disorder: the SHIFT Study | Semaglutide | Addiction & substance use · n = 40 | — |
| HUMAN-TRIAL | evidence | Phase III Study of UBT251 Injection in Patients With Type 2 Diabetes With Inadequate Glycemic Control on Metformin ± Sulfonylurea/SGLT2 Inhibitor Therapy (UNIGUIDE-2) | Semaglutide | Glycemic control · human-rct · n = 956 | — |
| HUMAN-TRIAL | evidence | PEG-rhGH and Semaglutide Combination Therapy in Non-Diabetic Obese Adults | Semaglutide | Weight & fat loss · human-rct · n = 212 | — |
| HUMAN-TRIAL | evidence | Prediction of the SEPRA Diabetes Trial in Healthcare Claims Data | Semaglutide | Glycemic control · human-observational · n = 2316 | — |
| HUMAN-TRIAL | evidence | Comparative Effectiveness of Oral Semaglutide vs Sitagliptin Among Individuals With Heart Failure With Preserved Ejection Fraction (STEP-HFpEF DM ORAL) | Semaglutide | human-observational · n = 25664 | — |
| HUMAN-TRIAL | evidence | A Multicentre, Prospective, Single-arm, Non-interventional Regulatory Post-marketing Surveillance (rPMS) Study to Investigate the Safety and Effectiveness of Wegovy® (Semaglutide) in Patients With Obesity and Patients With Overweight in Routine Clinical Practice in Korea | Wegovy | Weight & fat loss · human-observational · n = 840 | — |
| HUMAN-TRIAL | evidence | DECODE - Haemodynamic Effects Of Semaglutide and Tirzepatide - a Series of Pilot Studies | Semaglutide | Lipid & cardiovascular markers · human-rct · n = 112 | — |
| HUMAN-TRIAL | evidence | A Research Study to Compare a Medicine Called Semaglutide Against Placebo in People With Peripheral Arterial Disease and Type 2 Diabetes | Semaglutide | Glycemic control · human-rct · n = 792 | — |
| HUMAN-TRIAL | evidence | Special Use - Results Surveillance on Long-term Use With Wegovy® | Wegovy | Weight & fat loss · human-observational · n = 1071 | — |
| HUMAN-TRIAL | evidence | Pharmacokinetic Similarity, Safety, and Immunogenicity of Semaglutide Injection and Ozempic ® Injection in Healthy Subjects. | Ozempic | Glycemic control · human-rct · n = 68 | — |
| HUMAN-TRIAL | evidence | Testing the Efficacy, Safety, and PK of 20E in Patients With Obesity Who Are Starting Treatment With the GLP-1 Agonist Semaglutide for Weight Loss. | Ozempic | Weight & fat loss · human-rct · n = 164 | — |